New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.
FDA warning letter reveals systemic failures in Novo Nordisk’s semaglutide safety reporting. Details on 15-day reporting violations, deaths, and suicides not reported to FDA. Regulatory analysis and consequences.
In a major industry shift, Hims & Hers will ditch compounded GLP-1s to offer branded Wegovy and Ozempic at self-pay prices following a settlement with Novo Nordisk.
Novo Nordisk announced today a significant reduction in US list prices for
Wegovy, Ozempic, and Rybelsus, with prices dropping to $675 per month effective
January 1, 2027. The price cuts approximately 50% for Wegovy and 35% for Ozempic
represent a major step toward improving patient access and affordability for
obesity and type 2 diabetes treatments.
European Commission approves Wegovy 7.2 mg for obesity treatment. Clinical trial shows 21% average weight loss with 84% from fat mass. Now available across EU.
Novo Nordisk has officially launched the Wegovy® pill, the first-ever oral GLP-1 medication for weight management in adults. Following FDA approval in late 2025, this once-daily pill offers a needle-free alternative to injections, demonstrating an average weight loss of up to 17% in clinical trials. With tiered pricing starting at $149 per month for self-pay patients, oral Wegovy is now available through major U.S. pharmacies and select telehealth platforms.
In a significant legal victory, Novo Nordisk announced on December 31, 2025, that China’s Supreme People’s Court had issued a final, positive ruling upholding the [Read More…]
The FDA has officially approved the first-ever oral version of Wegovy, a once-daily tablet from Novo Nordisk. With clinical trials showing a 16.6% average weight loss, this landmark approval offers a needle-free alternative for obesity management and cardiovascular protection starting in January 2026.
Novo Nordisk has officially submitted a New Drug Application to the FDA for CagriSema, a first-of-its-class once-weekly injection for chronic weight management. Combining semaglutide with a novel amylin analogue, clinical data from the REDEFINE program shows the treatment can achieve over 20% weight loss in adults with obesity.
